Company Overview

FluoroPharma Medical, Inc. (FPMI) is a molecular imaging and radiopharmaceutical development company focused on diagnostic agents used in positron emission tomography (PET) imaging. The company has historically operated within the healthcare, biotechnology, and nuclear medicine industries, with an emphasis on cardiovascular and oncology imaging technologies. Its primary business objective has been the development of fluorine-18–based PET imaging compounds intended to improve the detection and characterization of disease processes such as coronary artery disease and cancer.

The company’s principal value proposition centered on developing PET tracers with longer half-lives and potentially broader clinical utility compared with traditional imaging isotopes. Public filings and historical investor materials indicate that FPMI pursued proprietary radiopharmaceutical candidates designed to support non-invasive imaging and diagnostic workflows. The company evolved from an early-stage diagnostic imaging developer into a clinically focused radiopharmaceutical enterprise; however, publicly available information regarding recent commercialization progress, revenue scale, or active operating status remains limited. Data inconclusive based on available public sources regarding the company’s current commercial operations.

Business Operations

Historically, FPMI’s operations were concentrated around the research, development, and potential commercialization of PET imaging agents. The company’s business model relied primarily on advancing proprietary imaging compounds through preclinical and clinical development, with anticipated future revenue opportunities tied to licensing, commercialization partnerships, and diagnostic imaging adoption. Public disclosures identified cardiovascular imaging as a core strategic area, particularly through radiotracers intended to evaluate myocardial perfusion and metabolic activity.

The company’s operations appear to have been primarily U.S.-based, with development activities tied to clinical research institutions and radiopharmaceutical manufacturing infrastructure. Public records reference proprietary fluorine-18 imaging technology assets and intellectual property related to PET diagnostics. There is limited verified public information regarding active international subsidiaries, large-scale commercial manufacturing operations, or major revenue-generating business divisions. Data inconclusive based on available public sources concerning significant current joint ventures or operating subsidiaries.

Strategic Position & Investments

FPMI’s strategic direction historically focused on advancing differentiated PET imaging agents that could address limitations associated with conventional nuclear imaging technologies. The company emphasized fluorine-18 radiotracers because of their logistical advantages, including longer isotope half-life relative to certain competing agents, potentially enabling broader distribution through centralized manufacturing networks. Strategic efforts were directed toward clinical validation, regulatory advancement, and positioning imaging compounds for eventual adoption in cardiovascular diagnostics.

Publicly available information indicates that the company pursued investment into clinical-stage radiopharmaceutical development rather than diversification into broader pharmaceutical markets. Historical filings and investor communications referenced efforts to strengthen intellectual property and clinical partnerships. However, there is limited independently verifiable evidence of major acquisitions, large institutional portfolio holdings, or substantial operating subsidiaries comparable to larger radiopharmaceutical companies. Data inconclusive based on available public sources regarding recent financing activity, emerging technology investments, or active acquisition programs.

Geographic Footprint

FPMI’s operational footprint was primarily concentrated in the United States, where the company maintained its corporate activities and research focus. Its development efforts were associated with U.S.-based clinical and regulatory pathways, including interactions related to imaging-agent development and clinical testing. Public records do not indicate a broad multinational commercial infrastructure or extensive overseas operating divisions.

The company’s market relevance was tied more to participation in the global molecular imaging and nuclear medicine sector than to a large international operating presence. While PET imaging technologies have worldwide clinical applications, publicly available disclosures provide limited evidence of significant direct operations across Europe, Asia-Pacific, or other major international healthcare markets. Data inconclusive based on available public sources regarding current international operational scale.

Leadership & Governance

Publicly available information regarding FPMI leadership has varied across reporting periods, and some records appear dated due to limited recent disclosures. Historically, the company was led by executives with backgrounds in biotechnology, diagnostic imaging, and healthcare commercialization. Corporate governance appeared consistent with an early-stage publicly traded biotechnology company structure focused on research oversight, financing, and regulatory strategy.

Key executives and directors identified in historical public filings and investor materials include:

• Thijs Spoor – Former President and Chief Executive Officer
• Dr. David Elmaleh – Founder and scientific contributor associated with radiopharmaceutical development initiatives
• Michael Delfino – Former Chief Financial Officer

Leadership strategy historically emphasized clinical advancement of proprietary PET imaging compounds, protection of intellectual property, and establishing positioning within the molecular diagnostics market. More recent governance and executive data could not be consistently verified across multiple current public sources.